Dasatinib, nilotinib and Bosutinib, the second gerneration inhibitors of c-abl and PDGF receptors, serve as salvage therapies for the treatment of refractory chronic myeloid leukemia as well as patients with intolerance to Imatinib [47,48]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.